December 16, 2021 at 8:00 AM EST Cross-reactivity will be assessed using samples from Phase II clinical participants and in...
Business
Dr. Cummings Brings Nearly Three Decades of Experience to New Role SOUTH SAN FRANCISCO, Calif., Sept. 27, 2021 /PRNewswire/ -- Vaxart, Inc. (NASDAQ: VXRT),...
Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model July 09, 2019 08:00 AM Eastern Daylight Time...
May18,2020 Candidate: VXA-CoV2-1 Category: VAX Type: Oral recombinant vaccine administered by room temperature-stable tablet, and based on proprietary VAAST™ Platform. The vaccine is...
Vaxart’s oral COVID-19 vaccine candidate has joined the handful of experimental vaccines being studied as part of President Donald Trump's...
Purchase expected to give Vaxart greater control over manufacturing schedules SOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) --...
Interesting line I noted many months ago in an NY Times article about a new book about pandemics and epidemics....